JOHNSON & JOHNSON
For the period ended Dec 28, 2025. Filed Feb 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 11, 2026
JNJ$282.11+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated balance sheets
Johnson & Johnson and subsidiaries consolidated balance sheets
At December 28, 2025 and December 29, 2024
(Dollars in Millions Except Share and Per Share Amounts) (Note 1)
| 2025 | 2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents (Notes 1 and 2) | $19,709 | 24,105 |
| Marketable securities (Notes 1 and 2) | 393 | 417 |
| Accounts receivable trade, less allowances $183 (2024, $167) | 17,178 | 14,842 |
| Inventories (Notes 1 and 3) | 14,191 | 12,444 |
| Prepaid expenses and other receivables | 4,153 | 4,085 |
| Total current assets | 55,624 | 55,893 |
| Property, plant and equipment, net (Notes 1 and 4) | 23,169 | 20,518 |
| Intangible assets, net (Notes 1 and 5) | 50,403 | 37,618 |
| Goodwill (Notes 1 and 5) | 48,772 | 44,200 |
| Deferred taxes on income (Note 8) | 6,874 | 10,461 |
| Other assets | 14,368 | 11,414 |
| Total assets | $199,210 | 180,104 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities | ||
| Loans and notes payable (Note 7) | $8,495 | 5,983 |
| Accounts payable | 11,991 | 10,311 |
| Accrued liabilities | 8,594 | 8,549 |
| Accrued rebates, returns and promotions | 19,124 | 17,580 |
| Accrued compensation and employee related obligations | 4,534 | 4,126 |
| Accrued taxes on income (Note 8) | 1,388 | 3,772 |
| Total current liabilities | 54,126 | 50,321 |
| Long-term debt (Note 7) | 39,438 | 30,651 |
| Deferred taxes on income (Note 8) | 6,791 | 2,448 |
| Employee related obligations (Notes 9 and 10) | 6,957 | 7,255 |
| Long-term taxes payable (Note 1) | 486 | 390 |
| Other liabilities | 9,868 | 17,549 |
| Total liabilities | 117,666 | 108,614 |
| Commitments and Contingencies (Note 19) | ||
| Shareholders’ equity | ||
| Preferred stock — without par value (authorized and unissued 2,000,000 shares) | — | — |
| Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) | 3,120 | 3,120 |
| Accumulated other comprehensive income (loss) (Note 13) | (14,930) | (11,741) |
| Retained earnings and Additional-paid-in-capital | 168,978 | 155,791 |
| Less: common stock held in treasury, at cost (Note 12) (711,904,000 shares and 712,921,000 shares) | 75,624 | 75,680 |
| Total shareholders’ equity | 81,544 | 71,490 |
| Total liabilities and shareholders’ equity | $199,210 | 180,104 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.